Epigenetic regulation of MMP-11 and -16 expression in human prostate cancer: the role of KDM6A
Epigenomics · 12.12.2025 · 17 (18) · 1367-1380
DOI: 10.1080/17501911.2025.2586858 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epigenomics, online erschienen am 10.11.2025. Verfasst von Gökçe Yıldırım-Buharalıoğlu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Department of Pharmacology, Ege University, Bornova, Izmir, Turkey. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Prostatic Neoplasms, Histone Demethylases, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 84 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
AIMS: Matrix metalloproteinases (MMPs) promote prostate cancer (PCa) progression by degrading the extracellular matrix and enhancing metastasis. PCa is considered an "epigenetic catastrophe" due to disrupted histone modifications caused by chromatin-modifying enzyme dysregulation. We previously showed that lysine demethylase 6A (KDM6A) and 6B (KDM6B) are higher in metastatic PCa (LNCaP) versus benign prostatic hyperplasia (BPH-1). We investigated whether their elevation contributes to MMP upregulation. METHODS AND RESULTS: LNCaP cells were treated with the KDM6 inhibitor GSK-J4, and mRNA levels of 23 MMPs were quantified by RT-qPCR. GSK-J4 reduced mRNA levels of 6 MMPs (MMP-7, -8, -11, -15, -16, and -19) out of 23. Decline in pre-spliced mRNA levels of MMP-7, -11, and -16 by GSK-J4 suggested transcriptional changes; only MMP-11 and -16 exhibited corresponding protein decreases. Among downregulated MMPs, MMP-7, -11, -15 and -16 mRNA were higher in LNCaP versus BPH-1, confirmed at protein level for MMP-11 and -16. KDM6A - but not KDM6B - siRNA reduced MMP-11 and -16 expression. GSK-J4 increased histone3 lysine27 trimethylation (H3K27me3) enrichment at MMP-11 and -16 promoters, as shown by Chromatin Immunoprecipitation (ChIP). CONCLUSION: KDM6A demethylates H3K27me3 at MMP-11 and -16 promoters, sustaining their enhanced expression in PCa and revealing a novel epigenetic mechanism driving metastasis-associated protease expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Pharmacy, Department of Pharmacology, Ege University, Bornova, Izmir, Turkey.
- Faculty of Pharmacy, Department of Biochemistry, Ege University, Bornova, Izmir, Turkey.
- Faculty of Pharmacy, Department of Pharmacology, Izmir Katip Çelebi University, Balatçık, Cigli, Izmir, Turkey.
Zitieren
APA
Yıldırım-Buharalıoğlu, G., İlhan, R., Çakmak, Y., & Buharalıoğlu, C. K. (2025). Epigenetic regulation of MMP-11 and -16 expression in human prostate cancer: the role of KDM6A. Epigenomics, 17(18), 1367-1380. https://doi.org/10.1080/17501911.2025.2586858
Vancouver
Yıldırım-Buharalıoğlu G, İlhan R, Çakmak Y, Buharalıoğlu CK. Epigenetic regulation of MMP-11 and -16 expression in human prostate cancer: the role of KDM6A. Epigenomics. 2025;17(18):1367-1380. doi:10.1080/17501911.2025.2586858
BibTeX
@article{YldrmBuharalolu2025,
author = {Yıldırım-Buharalıoğlu, Gökçe and İlhan, Recep and Çakmak, Yaren and Buharalıoğlu, C Kemal},
title = {Epigenetic regulation of MMP-11 and -16 expression in human prostate cancer: the role of KDM6A},
journal = {Epigenomics},
year = {2025},
volume = {17},
number = {18},
pages = {1367--1380},
doi = {10.1080/17501911.2025.2586858}
}
EUVIMED